Hepatocellular carcinoma (HCC) · line 1 · Atezolizumab + Bevacizumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-ATEZO-BEV`

ID	`IND-HCC-SYSTEMIC-1L-ATEZO-BEV`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HCC-2023` `SRC-IMBRAVE150-FINN-2020` `SRC-NCCN-HCC-2025`

Notes

1L systemic HCC default — Child-Pugh A, ECOG ≤1, varices managed. Etiology rails (parallel to indication selection): HBV+ → entecavir/TDF prophylaxis throughout + ≥12 mo post (RF-HCC-HBV-REACTIVATION-RISK + SUP-HBV-PROPHYLAXIS); HCV-RNA+ → DAA (SOF/VEL or glec/pibr) before or concurrent with atezo+bev. Both pathways operate via parallel supportive_care, not by shifting atezo+bev → durva+treme.

Used By

Algorithms

ALGO-HCC-SYSTEMIC-1L - ALGO-HCC-SYSTEMIC-1L